Unilever's Relaxed Positioning Holds Into Thursday's Print

UL reports Q3 results on Thursday with short sellers making only the most modest commitments against the stock, and the broader market showing no urgency to hedge.

Short interest has drifted between 4.7 million and 5.6 million shares over the past six weeks, with no decisive directional move. The most recent reading of 4.7 million shares represents a 2.3% daily decline and leaves the month-on-month change at roughly 9%, almost entirely explained by a mid-October spike that has since unwound. Borrow costs have collapsed over the same period, falling 43% in a week to just 0.26%, the lowest level in the 30-day window. Availability is extraordinarily loose: roughly 97 million shares remain available to borrow against those already lent out, a ratio well above any historical stress point.

Options positioning is equally unremarkable. The put/call ratio of 0.81 is barely above its 20-day average of 0.80, with a z-score of 0.60, no defensive loading at all. That picture has not changed materially since the previous preview a week ago, when the ratio was 0.80 and equally flat. Nothing in the derivatives market suggests investors are bracing for an unwelcome surprise.

The substantive question going into Thursday is whether October's 4.9% price gain can be sustained once the numbers are in the open. Q3 revenue came in at 4.2% organic growth, beating the 3.1% consensus, and full-year guidance was lifted to 3.5% from 3.0%, according to a recent company update. The PE multiple has expanded nearly a full point over the past 30 days to 17.6x, and price-to-book has risen by 0.77 to 7.9x, reflecting a market that has already partially rewarded the guidance lift. The ORTEX short score of 28.8, ranking in the 91st percentile for the sector, reinforces the picture of a stock where bearish conviction is structurally low. BlackRock reported a 7.6% passive stake in an April 2025 filing, though that disclosure is now well over a year old.

The last comparable print, April's Q1 results, produced virtually no first-day move, with a near-zero daily reaction before a modest 3.9% recovery over the following five trading days. Thursday's print will test whether the raised guidance and emerging-market growth story can justify a valuation that has re-rated meaningfully higher over the past month.